中文
| Catalogue |
|
|
| Recommend Products |
Tessa Therapeutics.
Singapore, Manufacturer, Hits: 496, Updated:6/14/2022
singapore |
Company Profile
-
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (Phase 2). TT11 has been granted RMAT designation by the FDA and PRIME designation by European Medicine Agency. Tessa is also advancing an allogeneic “off-the shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com.
Company News
- Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of ... 6/26/2023
- Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in ... 6/19/2023
- Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th Interna... 5/31/2023
- Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023 1/4/2023
- Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Aut... 12/13/2022
- Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘... 11/8/2022
- Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022 11/3/2022
- Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific... 9/15/2022
- Tessa Therapeutics Appoints Thomas Willemsen as President and CEO 8/22/2022
- Tessa Therapeutics to Host Scientific Session on CD30 CAR-T Targeting of CD30+ Lymphomas at the SD... 6/14/2022